GlaxoSmithKline plc (GSK)
Company Info
US37733W1053
37733W105
Jul 9, 1986
Highlights
$73.63B
$1.56
22.77
0.75
$31.27B
$22.46B
$6.33B
$33.35 - $45.36
$44.69
0.72%
3.29
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in GlaxoSmithKline plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
GlaxoSmithKline plc had a return of -6.46% year-to-date (YTD) and -1.51% in the last 12 months. Over the past 10 years, GlaxoSmithKline plc had an annualized return of 1.53%, while the S&P 500 had an annualized return of 11.16%, indicating that GlaxoSmithKline plc did not perform as well as the benchmark.
GSK
-6.46%
-12.50%
-24.30%
-1.51%
-1.61%
1.53%
^GSPC (Benchmark)
23.62%
0.54%
11.19%
30.63%
13.61%
11.16%
Monthly Returns
The table below presents the monthly returns of GSK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 6.42% | 7.28% | 2.31% | -3.34% | 8.93% | -14.00% | 0.70% | 14.32% | -6.90% | -10.08% | -6.46% | ||
| 2023 | 0.34% | -1.87% | 3.82% | 1.26% | -5.84% | 6.07% | -0.20% | -0.21% | 3.19% | -1.52% | 1.82% | 2.97% | 9.71% |
| 2022 | 1.63% | -5.26% | 4.06% | 3.95% | -2.28% | -0.84% | -4.84% | -22.10% | -9.39% | 12.71% | 5.30% | 1.59% | -18.27% |
| 2021 | 1.22% | -8.19% | 6.19% | 4.62% | 5.22% | 2.71% | 0.80% | 2.76% | -6.21% | 10.78% | -1.67% | 7.25% | 26.63% |
| 2020 | -0.40% | -12.21% | -6.51% | 11.03% | 0.74% | -2.70% | -1.15% | -0.65% | -4.95% | -11.21% | 11.48% | 0.03% | -17.78% |
| 2019 | 2.59% | 4.44% | 3.54% | -1.58% | -4.89% | 3.57% | 3.15% | 1.87% | 2.65% | 7.31% | 0.38% | 3.32% | 29.12% |
| 2018 | 5.75% | -1.54% | 7.60% | 2.66% | 2.35% | -0.52% | 3.18% | -1.46% | -0.81% | -2.76% | 8.47% | -8.74% | 13.68% |
| 2017 | 2.08% | 6.97% | 1.64% | -2.99% | 9.39% | -2.51% | -6.03% | 0.50% | 0.92% | -10.27% | -2.44% | 1.17% | -3.07% |
| 2016 | 2.33% | -3.41% | 4.86% | 5.82% | 0.01% | 2.29% | 3.99% | -2.50% | -0.76% | -7.23% | -4.46% | 1.91% | 1.97% |
| 2015 | 2.95% | 9.34% | -2.68% | -0.00% | -2.64% | -6.13% | 4.30% | -4.54% | -6.06% | 11.99% | -4.61% | -0.40% | -0.36% |
| 2014 | -3.47% | 9.97% | -4.49% | 3.63% | -1.47% | -0.85% | -9.56% | 2.85% | -6.37% | -1.04% | 3.48% | -7.99% | -15.76% |
| 2013 | 4.92% | -2.02% | 6.54% | 10.08% | 1.32% | -3.48% | 1.98% | 0.92% | -1.41% | 4.90% | 1.73% | 0.89% | 28.81% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of GSK is 41, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
GlaxoSmithKline plc provided a 4.67% dividend yield over the last twelve months, with an annual payout of $1.56 per share.
| Period | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $1.56 | $1.39 | $1.68 | $2.21 | $2.06 | $2.05 | $2.16 | $2.06 | $2.77 | $2.45 | $2.65 | $2.41 |
Dividend yield | 4.67% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% | 4.43% |
Monthly Dividends
The table displays the monthly dividend distributions for GlaxoSmithKline plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | $0.41 | $0.00 | $0.00 | $0.38 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $0.39 | $1.56 | |
| 2023 | $0.00 | $0.34 | $0.00 | $0.00 | $0.35 | $0.00 | $0.00 | $0.36 | $0.00 | $0.00 | $0.34 | $0.00 | $1.39 |
| 2022 | $0.00 | $0.62 | $0.00 | $0.00 | $0.35 | $0.00 | $0.00 | $0.39 | $0.00 | $0.00 | $0.32 | $0.00 | $1.68 |
| 2021 | $0.00 | $0.63 | $0.00 | $0.00 | $0.53 | $0.00 | $0.00 | $0.53 | $0.00 | $0.00 | $0.52 | $0.00 | $2.21 |
| 2020 | $0.00 | $0.60 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.50 | $0.00 | $2.06 |
| 2019 | $0.00 | $0.60 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.46 | $0.00 | $0.00 | $0.49 | $0.00 | $2.05 |
| 2018 | $0.00 | $0.64 | $0.00 | $0.00 | $0.53 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.49 | $0.00 | $2.16 |
| 2017 | $0.00 | $0.58 | $0.00 | $0.00 | $0.49 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.50 | $0.00 | $2.06 |
| 2016 | $0.00 | $1.25 | $0.00 | $0.00 | $0.55 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.46 | $0.00 | $2.77 |
| 2015 | $0.00 | $0.70 | $0.00 | $0.00 | $0.58 | $0.00 | $0.00 | $0.59 | $0.00 | $0.00 | $0.58 | $0.00 | $2.45 |
| 2014 | $0.00 | $0.75 | $0.00 | $0.00 | $0.64 | $0.00 | $0.00 | $0.65 | $0.00 | $0.00 | $0.61 | $0.00 | $2.65 |
| 2013 | $0.69 | $0.00 | $0.00 | $0.55 | $0.00 | $0.00 | $0.55 | $0.00 | $0.00 | $0.62 | $0.00 | $2.41 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the GlaxoSmithKline plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the GlaxoSmithKline plc was 55.21%, occurring on Aug 13, 1993. Recovery took 765 trading sessions.
The current GlaxoSmithKline plc drawdown is 25.62%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -55.21% | Jan 10, 1992 | 404 | Aug 13, 1993 | 765 | Aug 22, 1996 | 1169 |
| -51.99% | Jan 7, 1999 | 889 | Jul 23, 2002 | 1190 | Apr 16, 2007 | 2079 |
| -49.7% | Apr 23, 2007 | 474 | Mar 9, 2009 | 785 | Apr 18, 2012 | 1259 |
| -46.08% | Jul 17, 1987 | 282 | Aug 25, 1988 | 454 | Jun 13, 1990 | 736 |
| -38.74% | Apr 14, 2022 | 114 | Sep 27, 2022 | 404 | May 7, 2024 | 518 |
Volatility
Volatility Chart
The current GlaxoSmithKline plc volatility is 6.01%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of GlaxoSmithKline plc compared to its peers in the Drug Manufacturers - General industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for GSK in comparison to other companies of the Drug Manufacturers - General industry. Currently, GSK has a PE value of 22.8. This PE ratio falls in the average range for the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for GSK in comparison to other companies of the Drug Manufacturers - General industry. Currently, GSK has a PEG value of 0.7. This PEG ratio falls in the average range for the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for GlaxoSmithKline plc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |